Pharmaceuticals
WuXi Biologics Receives AAA MSCI ESG Rating
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...
2023-11-08 08:30
1282
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor). * The vir...
2023-11-08 08:30
1576
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
* ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. * ESR1 mutations are present in up to 40% of ER+, HER2- advance...
2023-11-08 02:01
1460
Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...
2023-11-07 21:58
1042
Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs
* Company's eTurna™ delivery platform ensures unprecedented precision, safety * In-vivo biodistribution of mRNA into dermal cells, tissues shows high transfection efficiency, gene expression * Data presented at ASDS Annual Meeting MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Turn Biot...
2023-11-07 21:30
2248
Kexing Biopharm Attended CPHI Worldwide 2023
SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held inBarcelona, Spain. Kexing Biopharm exhibited more than ten kinds of high-quality medical products in the fields of tumor, autoimmune, anti-virus, etc., including Infliximab, Adalimumab, Bevacizumab,...
2023-11-07 20:09
1195
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)
HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...
2023-11-07 20:00
1690
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of advanced malign...
2023-11-07 14:14
1124
87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held inIreland from...
2023-11-07 12:31
1167
KN026 was Granted Breakthrough Therapy Designation by CDE
SUZHOU, China, Nov. 7, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced, that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) granted a Breakthrough Therapy d...
2023-11-07 08:51
1492
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Vietnam, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responde...
2023-11-07 08:15
1056
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Taiwan, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responden...
2023-11-07 08:15
1040
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Indonesia, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respon...
2023-11-07 08:15
1038
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including India, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondent...
2023-11-07 08:15
958
Lerna Bio unveils its first-in-class solution to combat liver failure
SINGAPORE, CAMBRIDGE, Mass. and SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Lerna Biopharma Pte. Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting inBoston organized by American Association for the Study of Liver Diseases (AA...
2023-11-06 22:00
1255
I-Mab Announces Participation at Jefferies and Piper Conferences in November
ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies...
2023-11-06 21:00
1093
Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published
JINAN, China, Nov. 6, 2023 /PRNewswire/ -- Recently, the results of the Phase I study for iparomlimab (R&D code: QL1604), developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journalFrontiers in Immunology (2022 Impact Factor: 7.3). The title of the paper is "A first-i...
2023-11-06 18:54
1306
'Listen to your patients for early identification of Peripheral Neuropathy' say leading Health Experts at P&G's #KNOWTHESIGNS Scientific Forum
* 1 in 2 Diabetics and 1 in 10 Pre-diabetics estimated to suffer from PN * Vitamin B Deficiency affects quality of life of ~ 19% of all Diabetics * Unveil NEW NENOIN Study results on how B Vitamins improve sensory symptoms, motor function and motor strength in PN JAKARTA, Indonesia, Nov. 6, 2...
2023-11-06 17:07
1578
Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42, a novel farnesoid X receptor (FXR) agonist, in healthy subjects ha...
2023-11-06 12:20
1455
The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval
YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug...
2023-11-06 09:11
1225
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 281 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 276 media titles]
2024-04-19 13:25
Most Read
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3817
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3083
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3003
